Clinical Policy: Doxycycline Hyclate (Acticlate, Doryx), Doxycycline (Oracea)
Defines medical necessity criteria, prior authorization and continuation requirements, dosing limits, covered indications (rosacea, acne vulgaris, malaria prophylaxis, FDA-approved acute infections) and exclusions for doxycycline formulations across commercial, HIM/ICHRA, and Medicaid lines of business for Centene-affiliated health plans.
Added ICHRA line of business and references to doxycycline hyclate (generic Acticlate).
Added step therapy bypass for Illinois HIM per IL HB 5395.
For rosacea, added requirement that member must use delayed release doxycycline (generic Oracea).
Doryx MPC 60 mg strength added to policy.
2Q 2026 annual review: references updated; no significant clinical changes.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.